CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC).
April 3, 2025
StoneCo Ltd. (STNE) Provides financial technology solutions to merchants in Brazil, including payment processing, banking services, and digital tools. Growth is fueled by rising fintech adoption, small business demand, and... Read More
April 3, 2025
CME Group Inc. (CME) Operates one of the world’s largest derivatives marketplaces, offering futures and options across asset classes. Growth is fueled by rising demand for risk management tools, increased... Read More
April 2, 2025
Goosehead Insurance, Inc. (GSHD) Goosehead Insurance, Inc. (GSHD) is a rapidly expanding American personal insurance agency that differentiates itself with a client-centric service model and advanced technology platform. The company’s... Read More
SJW Group (SJW) SJW Group, operating primarily through its subsidiaries, is a prominent player in the U.S. water utility sector. It focuses on the production, purchase, storage, purification, distribution, wholesale,... Read More
Urban Outfitters, Inc. (URBN) Urban Outfitters, Inc. (URBN) is a multinational lifestyle retail corporation headquartered in Philadelphia, Pennsylvania. It operates under various brand names including Urban Outfitters, Anthropologie, Free People,... Read More
Yum China Holdings, Inc. (YUMC) Yum China operates well-known restaurant brands like KFC, Pizza Hut, and Taco Bell across mainland China. The company holds exclusive rights to these brands in... Read More